Trauner, Michael

Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis

Mózes, F. E., Lee, J. A., Vali, Y., Alzoubi, O., Staufer, K., Trauner, M., Paternostro, R., Stauber, R. E., Holleboom, A. G., van Dijk, A.-M., et al. (2023) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 214

Novel therapeutic targets for cholestatic and fatty liver disease

Trauner, M., & Fuchs, C. D. (2022) · Gut

Liver Disease Diagnosis and TreatmentDrug Transport and Resistance Mechanisms

Cited by 204

Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis

Baghdasaryan, A., Fuchs, C. D., Österreicher, C. H., Lemberger, U. J., Halilbasic, E., Påhlman, I., Graffner, H., Krones, E., Fickert, P., Wahlström, A., et al. (2016) · Journal of Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 187

Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study

Trauner, M., Nevens, F., Shiffman, M. L., Drenth, J. P. H., Bowlus, C. L., Vargas, V., Andreone, P., Hirschfield, G. M., Pencek, R., Malecha, E. S., et al. (2019) · The Lancet Gastroenterology & Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 180

The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction

Schwabl, P., Hambruch, E., Seeland, B. A., Hayden, H., Wagner, M., Garnys, L., Strobel, B., Schubert, T.-L., Riedl, F., Mitteregger, D., et al. (2017) · Journal of Hepatology

Liver Disease and TransplantationLiver physiology and pathology

Cited by 178

Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis

Sanyal, A. J., Anstee, Q. M., Trauner, M., Lawitz, E. J., Abdelmalek, M. F., Ding, D., Han, L., Jia, C., Huss, R. S., Chung, C., et al. (2022) · Hepatology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 171

Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts

Fickert, P., Fuchsbichler, A., Moustafa, T., Wagner, M., Zollner, G., Halilbasic, E., Stöger, U., Arrese, M., Pizarro, M., Solís, N., et al. (2009) · The American Journal of Pathology

Liver physiology and pathologyLiver Disease Diagnosis and Treatment

Cited by 169

Nuclear receptors as therapeutic targets in cholestatic liver diseases

Zollner, G., & Trauner, M. (2009) · British Journal of Pharmacology

Drug Transport and Resistance MechanismsCholesterol and Lipid Metabolism

Cited by 146

Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC

Sydor, S., Best, J., Messerschmidt, I., Manka, P., Vilchez-Vargas, R., Brodesser, S., Lucas, C., Wegehaupt, A., Wenning, C., Aßmuth, S., et al. (2020) · Clinical and Translational Gastroenterology

Gut microbiota and healthLiver Disease Diagnosis and Treatment

Cited by 127

Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis

Reich, M., Spomer, L., Klindt, C., Fuchs, K., Stindt, J., Deutschmann, K., Höhne, J., Liaskou, E., Hov, J. R., Karlsen, T. H., et al. (2021) · Journal of Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 121

The association of histologic and noninvasive tests with adverse clinical and patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis

Younossi, Z. M., Anstee, Q. M., Wai-Sun Wong, V., Trauner, M., Lawitz, E. J., Harrison, S. A., Camargo, M., Kersey, K., Subramanian, G. M., Myers, R. P., et al. (2021) · Gastroenterology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 118

The challenges of primary biliary cholangitis: What is new and what needs to be done

Terziroli Beretta-Piccoli, B., Mieli-Vergani, G., Vergani, D., Vierling, J. M., Adams, D., Alpini, G., Banales, J. M., Beuers, U., Björnsson, E., Bowlus, C., et al. (2019) · Journal of Autoimmunity

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 114

Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis

Loomba, R., Huang, D. Q., Sanyal, A. J., Anstee, Q. M., Trauner, M., Lawitz, E. J., Ding, D., Ma, L., Jia, C., Billin, A., et al. (2023) · Gut

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 110

Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls

Murillo Perez, C. F., Fisher, H., Hiu, S., Kareithi, D., Adekunle, F., Mayne, T., Malecha, E., Ness, E., van der Meer, A. J., Lammers, W. J., et al. (2022) · Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 107

Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases

Lynch, K. D., Chapman, R. W., Keshav, S., Montano-Loza, A. J., Mason, A. L., Kremer, A. E., Vetter, M., de Krijger, M., Ponsioen, C. Y., Trivedi, P., et al. (2020) · Clinical Gastroenterology and Hepatology

Liver Diseases and ImmunityInflammatory Bowel Disease

Cited by 105

Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease

Fuchs, C., Traussnigg, S., & Trauner, M. (2016) · Seminars in Liver Disease

Liver Disease Diagnosis and TreatmentPeroxisome Proliferator-Activated Receptors

Cited by 100

Inhibition of monoacylglycerol lipase, an anti-inflammatory and antifibrogenic strategy in the liver

Habib, A., Chokr, D., Wan, J., Hegde, P., Mabire, M., Siebert, M., Ribeiro-Parenti, L., Le Gall, M., Lettéron, P., Pilard, N., et al. (2019) · Gut

Liver physiology and pathologyLiver Disease Diagnosis and Treatment

Cited by 91

Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial

Traussnigg, S., Schattenberg, J. M., Demir, M., Wiegand, J., Geier, A., Teuber, G., Hofmann, W. P., Kremer, A. E., Spreda, F., Kluwe, J., et al. (2019) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 88

Bile secretory function in the obese Zucker rat: evidence of cholestasis and altered canalicular transport function

Pizarro, M., Balasubramaniyan, N., Solís, N., Solar, A., Duarte, I., Miquel, J. F., Suchy, F. J., Trauner, M., Accatino, L., Ananthanarayanan, M., et al. (2004) · Gut

Drug Transport and Resistance MechanismsLiver Disease Diagnosis and Treatment

Cited by 87

PNPLA3 expression and its impact on the liver: current perspectives

Bruschi, F. V., Tardelli, M., Claudel, T., & Trauner, M. (2017) · Hepatic Medicine: Evidence and Research

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 81

Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2−/− mice by modulating composition, signalling and excretion of faecal bile acids

Fuchs, C. D., Paumgartner, G., Mlitz, V., Kunczer, V., Halilbasic, E., Leditznig, N., Wahlström, A., Ståhlman, M., Thüringer, A., Kashofer, K., et al. (2018) · Gut

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 76

Na + -taurocholate cotransporting polypeptide inhibition has hepatoprotective effects in cholestasis in mice

Slijepcevic, D., Roscam Abbing, R. L. P., Fuchs, C. D., Haazen, L. C. M., Beuers, U., Trauner, M., Oude Elferink, R. P. J., & van de Graaf, S. F. J. (2018) · Hepatology

Drug Transport and Resistance MechanismsLiver physiology and pathology

Cited by 73

The value of different CT‐based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis

Paternostro, R., Lampichler, K., Bardach, C., Asenbaum, U., Landler, C., Bauer, D., Mandorfer, M., Schwarzer, R., Trauner, M., Reiberger, T., et al. (2019) · Liver International

Nutrition and Health in AgingLiver Disease and Transplantation

Cited by 71

The non-steroidal FXR agonist cilofexor improves portal hypertension and reduces hepatic fibrosis in a rat NASH model

Schwabl, P., Hambruch, E., Budas, G. R., Supper, P., Burnet, M., Liles, J. T., Birkel, M., Brusilovskaya, K., Königshofer, P., Peck-Radosavljevic, M., et al. (2021) · Biomedicines

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 70